SCIENTIFIC AND INFORMATION-ANALYTICAL MAGAZINE

ISSN 1024-6177 (Print), ISSN 2618-9615 (Online)

JOURNAL DESCRIPTION

The Medical Radiology and Radiation Safety journal ISSN 1024-6177 was founded in January 1956 (before December 30, 1993 it was entitled Medical Radiology, ISSN 0025-8334). In 2018, the journal received Online ISSN: 2618-9615 and was registered as an electronic online publication in Roskomnadzor on March 29, 2018. It publishes original research articles which cover questions of radiobiology, radiation medicine, radiation safety, radiation therapy, nuclear medicine and scientific reviews. In general the journal has more than 30 headings and it is of interest for specialists working in thefields of medicine¸ radiation biology, epidemiology, medical physics and technology. Since July 01, 2008 the journal has been published by State Research Center - Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency. The founder from 1956 to the present time is the Ministry of Health of the Russian Federation, and from 2008 to the present time is the Federal Medical Biological Agency.

Members of the editorial board are scientists specializing in the field of radiation biology and medicine, radiation protection, radiation epidemiology, radiation oncology, radiation diagnostics and therapy, nuclear medicine and medical physics. The editorial board consists of academicians (members of the Russian Academy of Science (RAS)), the full member of Academy of Medical Sciences of the Republic of Armenia, corresponding members of the RAS, Doctors of Medicine, professor, candidates and doctors of biological, physical mathematics and engineering sciences. The editorial board is constantly replenished by experts who work in the CIS and foreign countries.

Six issues of the journal are published per year, the volume is 13.5 conventional printed sheets, 88 printer’s sheets, 1.000 copies. The journal has an identical full-text electronic version, which, simultaneously with the printed version and color drawings, is posted on the sites of the Scientific Electronic Library (SEL) and the journal's website. The journal is distributed through the Rospechat Agency under the contract № 7407 of June 16, 2006, through individual buyers and commercial structures. The publication of articles is free.

The journal is included in the List of Russian Reviewed Scientific Journals of the Higher Attestation Commission. Since 2008 the journal has been available on the Internet and indexed in the RISC database which is placed on Web of Science. Since February 2nd, 2018, the journal "Medical Radiology and Radiation Safety" has been indexed in the SCOPUS abstract and citation database.

Brief electronic versions of the Journal have been publicly available since 2005 on the website of the Medical Radiology and Radiation Safety Journal: http://www.medradiol.ru. Since 2011, all issues of the journal as a whole are publicly available, and since 2016 - full-text versions of scientific articles. Since 2005, subscribers can purchase full versions of other articles of any issue only through the National Electronic Library. The editor of the Medical Radiology and Radiation Safety Journal in accordance with the National Electronic Library agreement has been providing the Library with all its production since 2005 until now.

The main working language of the journal is Russian, an additional language is English, which is used to write titles of articles, information about authors, annotations, key words, a list of literature.

Since 2017 the journal Medical Radiology and Radiation Safety has switched to digital identification of publications, assigning to each article the identifier of the digital object (DOI), which greatly accelerated the search for the location of the article on the Internet. In future it is planned to publish the English-language version of the journal Medical Radiology and Radiation Safety for its development. In order to obtain information about the publication activity of the journal in March 2015, a counter of readers' references to the materials posted on the site from 2005 to the present which is placed on the journal's website. During 2015 - 2016 years on average there were no more than 100-170 handlings per day. Publication of a number of articles, as well as electronic versions of profile monographs and collections in the public domain, dramatically increased the number of handlings to the journal's website to 500 - 800 per day, and the total number of visits to the site at the end of 2017 was more than 230.000.

The two-year impact factor of RISC, according to data for 2017, was 0.439, taking into account citation from all sources - 0.570, and the five-year impact factor of RISC - 0.352.

Medical Radiology and Radiation Safety. 2019. Vol. 64. No. 3. P. 64–73

DOI: 10.12737/article_5cf3e4354d3276.60963732

D.V. Kuzmichev, Z.Z. Mamedli, A.A. Aniskin, A.V. Polinovskiy, J.M. Madyarov, S.I. Tkachev, A.V. Egorova, A.S. Aniskina

The Evolution of Neoadjuvant and Adjuvant Component of Treatment of Patients with Locally Advanced Rectal Cancer

1. N.N. Blokhin National Medical Research Center, Moscow, Ruissia;
2. N.I. Pirogov Russian National Research Medical University, Moscow, Ruissia. E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

D.V. Kuzmichev – Senior Researcher, PhD Med.;
Z.Z. Mamedli – Head of Dep., PhD Med.;
A.A. Aniskin – Resident;
A.V. Polinovskiy – Researcher, PhD Med.;
J.M. Madyarov – Doctor, PhD Med.;
S.I. Tkachev – Leading Researcher, Dr. Sci. Med., Prof.;
A.V. Egorova – PhD Med., Prof.;
A.S. Aniskina – Resident

Abstract

The results of numerous single-center and multicenter randomized and non-randomized studies on the treatment of patients with locally advanced rectal cancer (LARC) over a 70-year period are presented. The sequence of surgical, medicinal, radiation and chemoradiation treatment is represented. The doses and amount of radiation exposure are described, both in mono mode and with the use of various combinations of chemotherapeutic drugs in neoadjuvant and adjuvant regimens. The evolution of complex treatment that has shifted has shifted the emphasis to the use of chemoradiation therapy in the neoadjuvant period, and the introduction of new chemotherapeutic drugs and regimens have significantly increased the survival rates among patients with LARC. The approaches to the treatment of patients with LARC are not static and are constantly being improved. This literature review shows the chronological sequence and major current trends in the neoadjuvant and adjuvant components of the treatment of patients with locally advanced rectal cancer.

Key words: locally advanced rectal cancer, complex treatment, consolidation chemotherapy, induction chemotherapy, medical pathomorphosis

REFERENCES

  1. Kaprin AD, Starinsky VV, Petrova GV. Malignant tumors in Russia in 2015. Moscow, 2017:11-2 (Russian).

  2. The Beyond TME Collaborative. Brit J Surg. 2013;2(100(8)):1009-14.

  3. Aleksic M, Hennes N, Ulrich B. Surgical treatment of locally advanced rectal cancer. Options and strategies. Dig Surg. 1998(15):342-6.

  4. Fisher B, Wolmark N, Rockette H, et al. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J  Nat  Cancer Institute. 1988;80(1):21-9.

  5. Treurniet-Donker AD, van Putten WL, Wereldsma JC, et al. Postoperative radiation therapy for rectal cancer. An interim analysis of a prospective, randomized multicenter trial in The Netherlands. Cancer. 1991;67(8):2042-8.

  6. Balslev I, Pedersen M, Teglbjaerg PS. Postoperative radiotherapy in Dukes’ B and C carcinoma of the rectum and rectosigmoid. A randomized multicenter study. Cancer. 1986;58(1):22-8.

  7. Randomised trial of surgery alone versus surgery followed by radiotherapy for mobile cancer of the rectum. Medical Research Council Rectal Cancer Working Party. Lancet. 1996;348(9042):1610-4.

  8. André T, Boni C, Mounedji-Boudiaf L, Navarro M. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343-51.

  9. Twelves C, Wong A, Nowacki MP. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005;352(26):2696-704.

  10. Petersen SH, Harling H, Kirkeby LT, et al. Postoperative adjuvant chemotherapy in rectal cancer operated for cure. Cochrane Database Syst Rev. 2012. 3:CD004078.

  11. Hajibandeh S, Hajibandeh S. Systematic Review: Adjuvant Chemotherapy for Locally Advanced Rectal Cancer with respect to Stage of Disease. Int  Scholarly Res  Notices. 2015;2015. 710569.

  12. Gastrointestinal Tumor Study Group. Prolongation of the disease-free interval in surgically treated rectal carcinoma. N Engl J Med. 1985;312:1465-72.

  13. Moertel CG, Childs DS. Jr, Reitemeier RJ, et al. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet. 1969;25(2):865-7.

  14. Krook JE, Moertel CG, Gunderson LL, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med. 1991;324:709-15.

  15. Gastrointestinal Tumor Study Group. Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum. J Clin Oncol. 1992;10(4):549-57.

  16. NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA. 1990;264(11):1444-50.

  17. Haller DG, Catalano PG, MacDonald JS, Mayer RJ. Fluorouracil, leucovorin and levamisole adjuvant therapy for colon cancer: for-year results of INT-DO89. Proc. ASCO. 1997;16:265a, abs. 940.

  18. Andre T, Boni C, Mounedji-Boudiaf L, et al. Multicenter international study of oxaliplatin / 5-fluorouracil / leucovorin in the adjuvant treatment of colon cancer (MOSAIC) investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343-51.

  19. André T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27:3109-16.

  20. Shi Q, Sobrero A, Shields A, et al. Prospective pooled analysis of six phase III trials investigating duration of adjuvant oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration. J Clin Oncol. 2017;35:18.

  21. Petersen SH, Harling H, Kirkeby LT, et al. Postoperative adjuvant chemotherapy in rectal cancer operated for cure. Cochrane Database Syst Rev. 2012;3. CD004078.

  22. Fernández-Martos C, Pericay C, Aparicio J, et al. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study. J Clin Oncol. 2010;28:859-65.

  23. Frykholm GJ, Glimelius B, Påhlman L. Preoperative or postoperative irradiation in adenocarcinoma of the rectum: final treatment results of a randomized trial and an evaluation of late secondary effects. Dis Colon Rectum. 1993;36:564-72.

  24. Rodel C, Liersch T, Becker H, et al. Preoperative chemo­radiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol. 2012(13):679-87.

  25. Swedish Rectal Cancer Trial. Improved Survival with Preoperative Radiotherapy in Resectable Rectal Cancer. N Engl J Med. 1997;336:980-87.

  26. Folkesson J, Birgisson H, Pahlman L, et al. Swedish Rectal Cancer Trial: Long Lasting Benefits From Radiotherapy on Survival and Local Recurrence Rate. J Clin Oncol. 2005;23(24):5644-50.

  27. Birgisson H, Påhlman L, Gunnarsson U, Glimelius B. Adverse Effects of Preoperative Radiation Therapy for Rectal Cancer: Long-Term Follow-Up of the Swedish Rectal Cancer Trial. J Clin Oncol. 2005;23(34):8697-705.

  28. Sebag-Montefiore D, Stephens RJ, Steele R, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet. 2009;7(373(9666)):811-20.

  29. Bosset JF, Collette L, Calais G, et al. EORTC Radiotherapy Group Trial 22921. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;14(11(355)):1114-23.

  30. Fernández-Martos C, Nogué M, Cejas P, et al. The role of capecitabine in locally advanced rectal cancer treatment: an update. Drugs. 2012;28(8(72)):1057-73.

  31. Hofheinz R, Wenz F, Post S, et al. Capecitabine (Cape) versus 5-fluorouracil (5-FU)-based (neo)adjuvant chemoradiotherapy (CRT) for locally advanced rectal cancer (LARC): Long-term results of a randomized, phase III trial. 2011 ASCO Annual Meeting. 2011. Abstract 3504.

  32. Hofheinz RD, Wenz F, Post S, et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol. 2012;13:579-88.

  33. O’Connell MJ, Colangelo LH, Beart RW, et al. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from national surgical adjuvant breast and bowel project trial R-04. J Clin Oncol. 2014;32(18):1927-34.

  34. Aschele C, Cionini L, Lonardi S. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol. 2011;29(20):2773-80.

  35. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, et al. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Brit J Surg. 2006;93(10):1215-23.

  36. Chua YJ, Barbachano Y, Cunningham D. Neoadjuvantcapecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial. Lancet Oncol. 2010;11(3):241-8.

  37. Fernández-Martos C, Pericay C. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study. J Clin Oncol. 2010;28(5):859-65.

  38. Washington MK, Berlin J, Branton P, et al. Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum. Arch Pathol Lab Med. 2009;133(10):1539-51.

  39. Cercek A, Goodman KA, Hajj C, Weisberger E. Neoadjuvant chemotherapy first, followed by chemoradiation and then surgery, in the management of locally advanced rectal cancer. J Natl Compr Canc Netw. 2014;12(4):513-9.

  40. Dewdney A, Cunningham D, Tabernero J, et al. Multicenter Randomized Phase II Clinical Trial Comparing Neoadjuvant Oxaliplatin, Capecitabine, and Preoperative Radiotherapy with or without Cetuximab Followed by Total Mesorectal Excision in Patients With High-Risk Rectal Cancer (EXPERT-C). J Clin Oncol. 2012;30(14):1620-27.

  41. Nogue M, Salud A, Vicente P, et al. Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study. Oncologist. 2011;16:614-20.

  42. Habr-Gama A, Perez R.O, Sabbaga J, et al. Increasing the rates of complete response to neoadjuvantchemoradiotherapy for distal rectal cancer: results of a prospective study using additional chemotherapy during the resting period. Dis Colon Rectum. 2009;52:1927-34.

  43. Garcia-Aguilar J, Smith DD, Avila K, et al. Optimal timing of surgery after chemoradiation for advanced rectal cancer: preliminary results of a multicenter, nonrandomized phase II prospective trial. Ann Surg. 2011;254:97-102.

  44. Garcia-Aguilar J, Marcet J, Coutsoftides T, et al. Impact of neoadjuvant chemotherapy following chemoradiation on tumor response, adverse events, and surgical complications in patients with advanced rectal cancer treated with TME. Ann Surg. 2011;29(15): Suppl. 3514.

  45. Gao YH, Lin J.Z, An X, et al. Neoadjuvant Sandwich Treatment With Oxaliplatin and Capecitabine Administered Prior to, Concurrently With, and Following Radiation Therapy in Locally Advanced Rectal Cancer: A Prospective Phase 2 Trial. Int J Oncol Biol Phys. 2014;90(5):1153-60.

  46. Xiao J, Chen Z, Li W, et al. Sandwich-like neoadjuvant therapy with bevacizumab for locally advanced rectal cancer: a phase II trial. Cancer Chemother Pharmacol. 2015;76(1):21-7.

  47. Braendengen M, Tveit KM, Berglund A. Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. J Clin Oncol. 2008;26(22):3687-94.

  48. NCCN Clinical Practice Guidelines in Oncology, Version 2.2018. Rectal Cancer. 2018.

  49. Glimelius B, Pahlman L, Cervantes A. ESMO Guidelines Working Group. Rectal Cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(6):81-5.

  50. Biagi JJ, Raphael M, King WD, et al. The impact of time to adjuvant chemotherapy (AC) on survival in colorectal cancer (CRC): A systematic review and meta-analysis. J Clin Oncol. 2011;29(4):abstr 364.

For citation: Kuzmichev DV, Mamedli ZZ, Aniskin AA, Polinovskiy AV, Madyarov JM, Tkachev SI, Egorova AV, Aniskina AS. The Evolution of Neoadjuvant and Adjuvant Component of Treatment of Patients with Locally Advanced Rectal Cancer. Medical Radiology and Radiation Safety. 2019;64(3):64-73. (Russian).

DOI: 10.12737/article_5cf3e4354d3276.60963732

PDF (RUS) Full-text article (in Russian)

Contact Information

 

46, Zhivopisnaya st., 123098, Moscow, Russia Phone: +7 (499) 190-95-51. E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Journal location

Attendance

2950456
Today
Yesterday
This week
Last week
This month
Last month
For all time
1296
3041
7299
20395
48752
113593
2950456
Forecast today
6480

Your IP:216.73.216.106
Visitor Counter

© Журнал "Медицинская радиология и радиационная безопасность" 2020г.

Яндекс.Метрика

Наверх